OTCMKTS:HYPMY

Hypera (HYPMY) Stock Price, News & Analysis

$5.44
-0.05 (-0.91%)
(As of 04/24/2024 ET)
Today's Range
$5.44
$5.58
50-Day Range
$5.45
$7.12
52-Week Range
$5.30
$10.08
Volume
4,379 shs
Average Volume
8,239 shs
Market Capitalization
N/A
P/E Ratio
9.89
Dividend Yield
3.13%
Price Target
N/A
HYPMY stock logo

About Hypera Stock (OTCMKTS:HYPMY)

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

HYPMY Stock Price History

HYPMY Stock News Headlines

“The Biggest Bubble of All Time” – Here’s What to Do.
Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.
Hypera SA's Dividend Analysis
Hypera SA ADR HYPMY
“The Biggest Bubble of All Time” – Here’s What to Do.
Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.
HYPMY Hypera S.A.
Hypera S.A. goes ex dividend tomorrow
Sree Rayalaseema Hi-Strength Hypo Ltd.
Hypera Shares Fall 7.2% After Soft 3Q Earnings
Hypera S.A. (HYPE3.SA)
Hypera S.A. (HYPMY)
Symptoms Of Low Blood Sugar (Hypoglycemia)
See More Headlines
Receive HYPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hypera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:HYPMY
Fax
N/A
Employees
10,783
Year Founded
N/A

Profitability

Net Income
$330.11 million
Pretax Margin
20.24%

Debt

Sales & Book Value

Annual Sales
$1.59 billion
Cash Flow
$0.55 per share
Book Value
$3.26 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.45 billion
Optionable
Not Optionable
Beta
0.99
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Breno Toledo Pires de Oliveira
    CEO & Director
  • Mr. Adalmario Ghovatto Satheler do Couto
    Investor Relations Officer & CFO
  • Mr. Carlos Roberto Scorsi (Age 62)
    Chief Operating officer
  • Juliana Aguinaga Damião Salem
    Senior Legal Officer & Director
  • Joao Felipe Khamis Aguilar
    Risks & Compliance Officer
  • Mr. Luiz Eduardo Sales Clavis
    VP of Sales and Marketing & Director
  • Mauricio Christovam
    Senior Human Resources Officer
  • Mr. Hélio Segouras
    Head of Consumer Health

HYPMY Stock Analysis - Frequently Asked Questions

How have HYPMY shares performed in 2024?

Hypera's stock was trading at $7.16 at the beginning of 2024. Since then, HYPMY stock has decreased by 24.0% and is now trading at $5.44.
View the best growth stocks for 2024 here
.

Are investors shorting Hypera?

Hypera saw a drop in short interest in April. As of April 15th, there was short interest totaling 1,900 shares, a drop of 89.1% from the March 31st total of 17,400 shares. Based on an average daily volume of 18,000 shares, the short-interest ratio is currently 0.1 days.
View Hypera's Short Interest
.

Is Hypera a good dividend stock?

Hypera (OTCMKTS:HYPMY) pays an annual dividend of $0.17 per share and currently has a dividend yield of 3.07%. The dividend payout ratio is 30.91%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for HYPMY.

How do I buy shares of Hypera?

Shares of HYPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:HYPMY) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners